BioPharmSignal logoBioPharmSignal

Biotech News

Dyne Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights

Dyne Therapeutics (DYN)Dyne TherapeuticsEarnings

- Positive pre-BLA meeting completed with FDA for z-rostudirsen in exon 51 DMD; on track for BLA submission in Q2 2026 and potential launch in Q1 2027 - - Positive cardiopulmonary results and long-term dystrophin data from Phase 1/2 DELIVER trial of z-rostudirsen in exon 51 DMD presented at MDA

Related news

DYNDyne Therapeutics2026-07-29 20:30 EST

Dyne Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights

DYNDyne Therapeutics2026-03-02 12:30 EST

Dyne Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

View all latest news

Dyne Therapeutics

Oligonucleotide Therapeutics Dyne Therapeutics develops targeted oligonucleotide medicines for genetically driven muscle diseases. Its FORCE platform links therapeutic payloads to antibodies intended to improve delivery into muscle tissue. Duchenne Muscular Dystrophy Z-rostudirsen is designed for patients with Duchenne muscular dystrophy...

Recent company news

DYNDyne Therapeutics2026-08-20 20:05 EST

Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

DYNDyne Therapeutics2026-07-29 20:30 EST

Dyne Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights

DYNDyne Therapeutics2026-07-28 11:30 EST

Dyne Therapeutics Announces U.S. FDA Clearance of Investigational New Drug (IND) Application for DYNE-302 in Facioscapulohumeral Muscular Dystrophy (FSHD)

DYNDyne Therapeutics2026-07-24 20:05 EST

Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

DYNDyne Therapeutics2026-07-23 20:05 EST

Dyne Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares

Stock data

Close
26.10 USD
Market cap
2.85B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States